Alagille syndrome (ALGS) is a multisystem genetic disorder, usually of autosomal dominant inheritance, mainly caused by pathogenic variants in the JAG1 gene and, less frequently, in NOTCH2. These alterations affect the Notch signaling pathway, which is essential during embryonic development, and cause variable abnormalities in the liver, heart, skeleton, eyes, kidneys, and vascular system.
Alagille syndrome
Alagille syndrome is due in most cases to variants in JAG1, a gene that encodes a ligand of the Notch pathway; a small percentage of patients have variants in NOTCH2, which encodes a receptor of the same pathway. Notch signaling regulates communication between cells during organ formation and participates in the differentiation of intrahepatic bile ducts, cardiac structures, vertebrae, the eye, and blood vessels.
When JAG1 or NOTCH2 have pathogenic variants, this cellular communication is altered, and the development of various tissues can be incomplete or abnormal. The typical hepatic manifestation is paucity of intrahepatic bile ducts, which produces chronic cholestasis, jaundice, pruritus, xanthomas, fat malabsorption, and deficiency of fat-soluble vitamins. The disease follows an autosomal dominant pattern: a single altered copy can cause the disorder, although expressivity is highly variable, and some family members with the same variant may show mild or subclinical signs. The estimated incidence is around 1 in 30,000 to 50,000 live births.
Symptoms
The onset usually occurs in the first months of life, especially in cases with neonatal cholestasis. The main symptoms include persistent jaundice, intense pruritus, growth delay, and nutritional deficiencies. Heart disease is also common, especially peripheral pulmonary stenosis, vertebral anomalies such as butterfly vertebrae, posterior embryotoxon or other ocular abnormalities, characteristic facial features, and renal or vascular involvement. Severity is highly variable: some patients present with progressive liver disease requiring transplantation, while others have milder manifestations.
Disease management
Management is multidisciplinary and focuses on controlling cholestasis, pruritus, nutritional deficiencies, and cardiac, renal, or vascular complications. Liver treatment may include ursodeoxycholic acid, fat-soluble vitamin supplements, and nutritional support. For pruritus, medications such as rifampicin, bile acid sequestrant resins, or ileal bile acid transporter inhibitors, such as maralixibat, may be used when indicated.
Significant heart disease may require specialized intervention. In cases of liver failure or intractable pruritus, liver transplantation may be necessary, although it does not correct extrahepatic manifestations. Periodic clinical follow-up and family genetic counseling are recommended.
Genes analyzed
Bibliography
Spinner NB, Loomes KM, Krantz ID, et al. Alagille Syndrome. GeneReviews®.
Kohut TJ, Gilbert MA, Loomes KM. Alagille Syndrome: A Focused Review on Clinical Features, Genetics, and Treatment. Semin Liver Dis. 2021.
Ayoub MD, Kamath BM. Alagille Syndrome: Current Understanding of Pathogenesis, and Challenges in Diagnosis and Management. Clin Liver Dis. 2022.
Gilbert MA, Bauer RC, Rajagopalan R, et al. Alagille syndrome mutation update. Hum Mutat. 2019.
